- Ms. Levin is a seasoned CFO executive specializing in biotechnology corporate finance with broad expertise in accounting, investor relations, operations and strategy
- Dr. Porter has over 20 years of drug development expertise leading to successful NDA and sNDA product approvals for metabolic diseases
SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the appointment of Alyssa Levin as Chief Financial Officer and addition of Lisa E. Porter, M.D., to its Board of Directors.
ViaCyte logo. (PRNewsFoto/ViaCyte, Inc.)
"We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte. "Alyssa's business expertise will be a major asset as we execute our mission to fully realize the potential of ViaCyte's regenerative medicine platform, and our clinical programs will benefit greatly from Lisa's first-hand experience as both a physician and senior executive leading drug development strategy, clinical trials, and commercialization."
"With important milestones on the horizon, I am looking forward to working with Michael and our leadership team as we chart the course for ViaCyte as an industry leader providing potentially life-changing cell therapies," said Ms. Levin. "I am excited to lead the finance team as we pursue significant clinical and growth opportunities to create increased value across our pipeline."
"ViaCyte is leading the way into the clinic with new approaches to cell therapies that will help lessen the disease burden for people living with diabetes," said Dr. Porter. "As a physician, I am excited to see ViaCyte expand the potential of cell replacement therapies for diabetes and other disease indications to bring functional cures to patients in need."
Story continues
Appointee Bios
Most recently, Ms. Levin served as the Chief Financial Officer and Senior Vice President of Operations for Tentarix Biotherapeutics where she led the company's finance functions and played a key role in overseeing the expansion of the team as well as planning and operations setup. Previously, Ms. Levin was Chief Financial Officer at Bird Rock Bio, a clinical-stage bio-pharmaceutical company focused on the treatment of fibrotic, metabolic and inflammatory diseases. In this role, she managed all finance, accounting, investor relations, treasury and human resources. Additionally, she held positions with PwC LLP, Evomed LLC & Cosmederm Bioscience, Inc., and The Siegfried Group, LLP. Ms. Levin earned her B.A. from the University of British Columbia and an M.A. in Professional Accountancy from the University of Saskatchewan.
Dr. Porter currently serves as the Chief Medical Officer for Nano Precision Medical, a biopharmaceutical company focused on drug delivery to treat chronic metabolic diseases, where she is responsible for the strategy, direction and execution of clinical development plans for novel drug:device combinations. Prior to Nano Precision Medical, Dr. Porter was Chief Medical Officer for Eiger Biopharmaceuticals, Inc. and Dance Biopharma, Inc. (now Aerami Therapeutics). She previously held executive positions with Amylin Pharmaceuticals leading efforts that resulted in the approval of Bydureon, a GLP-1 agonist and the first once-weekly treatment for Type 2 diabetes. Additionally, Dr. Porter served in multiple clinical development and leadership roles at GlaxoSmithKline Pharmaceuticals and Zeneca Pharmaceuticals. Dr. Porter, a graduate of the College of William and Mary, earned her M.D. from Duke University School of Medicine and conducted her residency at Duke University Medical Center, then completed a fellowship in Endocrinology and Hypertension at Brigham & Women's Hospital.
About ViaCyte
ViaCyte is a privately held clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation. ViaCyte has the opportunity to use these technologies to address critical human diseases and disorders that can potentially be treated by replacing lost or malfunctioning cells or proteins. The Company's first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand ViaCyte's efforts, it has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. For more information, please visit http://www.viacyte.com and connect with ViaCyte on Twitter, Facebook, and LinkedIn.
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/viacyte-strengthens-management-team-with-appointment-of-alyssa-levin-as-chief-financial-officer-and-addition-of-lisa-porter-md-to-the-board-of-directors-301463612.html
SOURCE ViaCyte, Inc.
The rest is here:
ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of...
- Nano Medicine: Meaning, Advantages and Disadvantages - BioTechnology Notes - December 18th, 2022
- www.the-scientist.com - December 18th, 2022
- Applications of Nanotechnology - National Nanotechnology Initiative - December 18th, 2022
- Nanotechnology Timeline | National Nanotechnology Initiative - October 29th, 2022
- Nano based drug delivery systems: recent developments and future ... - October 21st, 2022
- The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review - Cureus - September 16th, 2022
- 'Glass bubble' nanocarrier boosts effects of combination therapy for pancreatic cancer - UCLA Newsroom - September 16th, 2022
- International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. - ETHealthWorld - September 16th, 2022
- Reebok Nano X2 Adventure Review: A Wild Way to Log Your Workouts - Gear Patrol - August 30th, 2022
- PhD within Particle Engineering job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 306487 - Times Higher Education - August 30th, 2022
- Nanoparticles' Role in Eliminating Cancer Cells - MedTech Outlook - August 22nd, 2022
- The first female astronaut from a North African nation will be a Tunisian military aviator - Atalayar - August 22nd, 2022
- Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition | npj Digital Medicine - Nature.com - August 22nd, 2022
- Reebok's Nano X2 Adventure Helps You Take Your Workouts Anywhere - Gear Patrol - August 14th, 2022
- How Houston's nonprofit funds early research that leads to breakthroughs like the COVID vaccine - Houston Chronicle - August 14th, 2022
- Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and... - July 27th, 2022
- Nanorobots Market to close to USD 19576.43 million with CAGR of 12.23% during the forecast period to 2029 - Digital Journal - July 27th, 2022
- Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development... - July 27th, 2022
- Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study - Business Wire - July 19th, 2022
- Columbia Business School and Columbia Engineering to Offer New "Dual MBA/Executive MS in Engineering and Applied Science" Program - Yahoo... - July 19th, 2022
- Internet of Nano Things Market is Poised to Grow at a CAGR of 24.12% during the Forecast Period of 2022-2031 - Digital Journal - July 11th, 2022
- Notable Thermal and Mechanical Properties of New Hybrid Nanostructures - AZoM - July 11th, 2022
- Eggshell and bioceramics: Break an egg to fix a tooth or two - BusinessLine - July 11th, 2022
- Nanomedicine in Central Nervous System Injury and Repair Market Share, Regional Growth Analysis, Upcoming Trends, Growth Factors and Leading... - July 11th, 2022
- Nanorobotics Market 2022 Research Report Analysis from Perspective of Segmentation and Industry Growth 2030 Designer Women - Designer Women - July 11th, 2022
- Artificial Intelligence in Medical Diagnostics Market Worth $9.38 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - July 11th, 2022
- $2.38M to test nano-engineered brain cancer treatment in mice - University of Michigan News - June 22nd, 2022
- New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The... - June 22nd, 2022
- Global Advanced Functional Materials Market To Be Driven By The Surging Demand From Medical Sector In The Forecast Period Of 2021-2026 Designer Women... - June 22nd, 2022
- An effective nano drug delivery and combination therapy for the treatment of Tuberculosis | Scientific Reports - Nature.com - June 13th, 2022
- Nanotechnology is poised to shape the future of Healthcare - ETHealthWorld - June 4th, 2022
- New Silence ALS Initiative is Giving Hope to Nano-Rare Patients - BioSpace - June 4th, 2022
- Nanotechnology in the Global Medical Applications Market 2022, Featuring Profiles of Abbott, Abraxis Bioscience, Elan, Orthovita, EyePoint... - May 15th, 2022
- Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian - May 2nd, 2022
- Nanomedicine Market to 2030 Insights and Forecast with Impact of COVID-19 | Abbott Laboratories, DiaSorin S.p.A, Invitae Corporation, Mallinckrodt... - May 2nd, 2022
- Cancer and Nanotechnology - National Cancer Institute - April 19th, 2022
- Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 - Digital Journal - April 19th, 2022
- ERDC researchers analyze resilience in nanotechnology supply chains - erdc.usace.army.mil - April 19th, 2022
- Nano Products Online Store | Nanoproducts, Nanoparticles ... - April 6th, 2022
- The Conrad Prebys Foundation to Support the Discovery and Development of Personalized ASO Medicines for Nano-rare Patients - Business Wire - March 25th, 2022
- Space the next frontier for cancer treatment? - Australian Jewish News - March 25th, 2022
- Surface Modification and Size Contribute to Nanoplastic Toxicity - AZoNano - January 20th, 2022
- Frontiers | Nanomedicine: Principles, Properties, and ... - January 5th, 2022
- Nanotechnology In Medicine: Huge Potential, But What Are ... - January 5th, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 5th, 2022
- 2009 show based on conspiracy theories is shared as proof of WHO working on COVID-19 vaccines to create permanent sterility - Factly - January 5th, 2022
- How to Improve Infectious Diseases with Nanotechnology - CIO Applications - January 5th, 2022
- Biodistribution of sphingolipid nanoemulsions with 68Ga | IJN - Dove Medical Press - August 31st, 2021
- Matrix Meats Adds to Team as Interest in Cultivated Meat Grows - PRNewswire - July 21st, 2021
- Nanomedicine in Central Nervous System Injury and Repair Market Report- Trends Key Programs Analysis and Competitive Landscape Analysis The Manomet... - June 23rd, 2021
- Nanomedicine is transforming healthcare innovation - Korea IT Times - June 6th, 2021
- The Future of Cancer Treatment Using Nanotechnology - AZoNano - June 6th, 2021
- Thomas Jefferson Awards Highlight Research and Service to the University - UVA Today - June 6th, 2021
- Global Nanobots Market 2020 | Research Report Covers | (COVID-19 Analysis) | Industry Research, Drivers, Top Trends | Global Analysis And Forecast to... - October 31st, 2020
- Nanox Signs With Ambra Health to Enable Image Access and Transfer with US Hospitals and Medical imaging Providers - BioSpace - October 31st, 2020
- Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 29th, 2020
- What is Nanoscience? | Outlook and How to Invest | INN - Investing News Network - September 23rd, 2020
- Interview: The NDB team on its revolutionary nano-diamond batteries - New Atlas - August 29th, 2020
- Opportunities in the World Nanotechnology Market to 2025 - Application of Nanotechnology in Wastewater Treatment and Enhanced Renewable Energy Driving... - August 12th, 2020
- Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters - BioSpace - June 17th, 2020
- Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire - June 17th, 2020
- Coronavirus threat to global Healthcare Nanotechnology (Nanomedicine) Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type... - June 15th, 2020
- Kanazawa University Research: Cell Removal as the Result of a Mechanical Instability - PR Newswire UK - June 15th, 2020
- Impact of Covid-19 on Nano Chemotherapy Market is Expected to Grow at an active CAGR by Forecast to 2026 | Top Players Dell Wyse, IBM, Microsoft -... - June 15th, 2020
- Evergreen Medical Acupuncture is now offering its own supplement and herbal products, Dr. Ficks Functional Farmacy! - TippNews DAILY - June 10th, 2020
- Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca - May 24th, 2020
- Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press - May 10th, 2020
- The future of medicine - Switzer Financial News - May 10th, 2020
- All your questions about how to wear a face mask -- answered - Action News Now - April 26th, 2020
- Edited Transcript of NANO earnings conference call or presentation 6-Feb-20 9:30pm GMT - Yahoo Finance - February 11th, 2020
- Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance - February 11th, 2020
- Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - BioSpace - February 11th, 2020
- Nano Medicine: Meaning, Advantages and Disadvantages - February 6th, 2020
- The Future Of Nano Medicine - February 6th, 2020
- VVUS Stock Jumps 70% on FDA Nod for New Formulation of Pancreaze - MicroSmallCap - February 6th, 2020
- Is the Lieber Arrest Linked to Military Brain Research and China? - Bryen's Blog - February 6th, 2020
- A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press - January 10th, 2020
- Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News - January 10th, 2020
- Triple Negative Breast Cancer Treatment Market Combining Therapies - Communal News - January 10th, 2020
- Our top 20 features of 2019 - COVER - January 5th, 2020